Complex Carbohydrate Modulation of Galectin Proteins for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer treatment have variable responses among individuals and often result in only partial success, necessitating approaches to enhance their efficacy.
Innovation Solution
The use of complex carbohydrate pharmaceutical compounds, such as galactoarabino-rhamnogalacturonate (GA-RG), either alone or in combination with targeted immunotherapies, to boost immune function by interacting with galectin proteins and modulating their activity, thereby increasing the activation of CD8+ and CD4+ T-cells and reducing tumor burden.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy is used to treat cancer, then the ability to attack and treat cancer is improved, but the response is variable and often only partially successful
Solution Approach 1:
The patent introduces complex carbohydrate pharmaceutical compounds as intermediary substances that modulate the immune system's response to cancer. These compounds act as mediators between the immunotherapy and the patient's immune system, enhancing the overall efficacy by boosting immune function through specific molecular interactions with galectin proteins.
Solution Approach 2:
The patent employs composite therapeutic approaches by combining complex carbohydrate compounds with targeted immunotherapies. This composite strategy integrates multiple mechanisms of action - the carbohydrate compounds modulate immune system-wide functions while the targeted immunotherapies provide specific anti-tumor activity, creating a synergistic effect that overcomes the limitations of either approach alone.
2Productivity
If complex carbohydrate compounds are used to boost immune function, then T-cell activation is increased, but the mechanism involves complex interactions with multiple galectin proteins
Solution Approach 1:
The complex carbohydrate pharmaceutical compounds exhibit multi-functionality by interacting with multiple galectin proteins (galectin-1, galectin-3, and other members of the galectin family) simultaneously. This universal binding capability allows a single compound to modulate various immune functions through different galectin targets, achieving enhanced T-cell activation without requiring multiple separate agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach leads to a significant increase in T-cell activation, tumor antigen-specific T-cells, and a substantial reduction in tumor size and metastases, with some treatments achieving a 50% reduction in total tumor burden.
Implementation Method 1
the specific GA-RG compounds can have the ability to interact with various domains of the class of galectin proteins, which includes galectins 1 through 15, and thereby inhibit, enhance or modulate their function
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.